Video Library

Filter

Editor's pick Exit

The road to exit

Kirsty is the Head of Investor Relations for Waymo, an autonomous driving company with a mission to make it safe and easy for people and things to get where they want to go. To date Waymo has raised $5.75bn from a world-class investor base including sovereign wealth funds, prominent growth tech investors and pension funds. Before this, Kirsty was the CEO of an OSI portfolio company spun out from the Oxford University Computer Sciences department, which was acquired by Waymo in 2019. She started her career at management consulting firm Oliver Wyman, before becoming an executive director for The AA.

Speakers

Kirsty Lloyds-Jones

Editor's pick Exit

Vaccitech & IPO

We are launching the Labs Series. We will talk with inspirational and exciting keynotes speakers to know more about their insights on topics you are interested in. We will hold these fireside chats monthly. Bill and Alex will share some of their insights when Vaccitech went public last year.

Speakers

Stakeholders

How To Run An Effective Board Meeting

Speakers

Goldman Sachs

Fundraising

LUX Capital, your thesis, European interest, process of DD, views on the deep-tech market and current COVID-19 climate

His thesis, European interest, process of DD, views on the deep-tech market and current COVID-19 climate

Speakers

Business Strategy and planning

Building a Business - Lecture 1 - 'How do I start a business?'

Professor Constantin Coussios, University of Oxford, discusses reasons for starting a business, provides practical insight on having a venture and what it takes to be an entrepreneur.

Speakers

Professor Constantin Coussios

Fundraising

How To Create A Pitch Deck That Any Investor Will Love

Bridger is the founder of Black Bridge Holdings - A privately run debt fund that has done over 290 deals in 38 states over the last 2 years.

Speakers

Bridger Pennington

Exit

Preparing for your IPO - a London Stock Exchange teach in

We have asked them to do a broad introduction to the AIM market from the perspective of IPO being a future option for any growth company to consider. With case studies drawn from the Tech and Healthcare sectors, they will cover: • An overview of public market activity since 1 March • Considerations - IPO vs. trade sale • Profile of investor groups that support the market • What investors look for in potential investments • How investors support companies as they scale (follow-on fund raising) • Market and investor characteristics - London vs. US • The path to IPO • Continuing obligations / life as a public company • Case studies – Tech & Healthcare This is intended to be a scene-setter and there will be time for questions and answers. The LSE have also offered to arrange to meet any OSI companies that would like a one on one session subsequent to the event.

Stakeholders

Boards: Recruiting Your Board Members

Have a wide lens. In this video, Brad Feld explains how it’s very easy to think about your own direct network, people you know or investors that invest in your company, and then go only one degree further. Thinking about recruiting board members in the early stages is powerful.

Speakers

Brad Feld

Fundraising

The Harvard Principles of Negotiation

Dr. Thomas Henschel explains 'The Harvard Approach' and how to get a Yes in every negotiation. 1. Separate the person from the issue. Don't take it to a negative personal level. 2. Do NOT Negotiate position-focused, but interest-oriented. 3. Carefully develop a set of criteria/requirements that a solution must fulfil, instead of rushing to a solution. 4. You should have several different options to choose from and evaluate them against the criteria.

Speakers

Erich Pommer Institut

Stakeholders

Boards: Managing Your Long-Term Relationship

Brad Feld encourages the creation of a board you can be comfortable with. One that you like spending time with. This will give you a chance to detach from the day-to-day of the business while you think about the business more broadly. In doing this, you want to create a relationship with each individual board member as well as a cohesion between the board members themselves.

Speakers

Brad Feld

Fundraising

How to pitch investors: the Startup Pitch, Pitch Deck and Pitch Techniques

Your startup pitch is a key asset in your fund raising toolkit for an angel pitch or a vc pitch . You need an effective pitch deck. How do you create an effective investor pitch? What topics should an investor pitch template (a pitch deck) include? What does an effective investor pitch template look like? How do you address the investor exit strategy and go to market strategy? I address those questions and many more in this video on how to pitch investors. What are some important pitch techniques you should incorporate? Why should you include your startup story in the pitch? Download a 1-page checklist covering all the Investor Pitch topics I cover in this video at: http://www.startupsos.com/investor-pi...

Speakers

StartupSOS

Fundraising

5 Pitch Mistakes Entrepreneurs Make, and How To Fix Them

Greylock Partners

Speakers

Brendan Baker (Greylock Partners)

Stakeholders

Boards: Choosing Your Board Members

Brad Feld encourages you to be as thoughtful about choosing your board members as you are about choosing your co-founders. You want a set of people with whom you really want to engage and work. Be deliberate about building your board and managing the expectations of the interactions.

Speakers

Brad Feld

Stakeholders

Board Functions and Responsibilities

Brad Feld explains why and how the board of directors is a formal construct that essentially provides governance for the company. Their duty, in a variety of formal and informal responsibilities, is to ultimately serve the best interest of the company. The CEO should create a transparency with the board that builds the board’s faith in the CEO as the person to run the company.

Speakers

Brad Feld

Product

Starbase Tour with Elon Musk

Musk restated that he believes everyone should be a chief engineer. Engineers need to understand the system at a high level to understand when they are making a bad optimization. As an example, Musk noted that an order of magnitude more time has been spent reducing engine mass than reducing residual propellant, despite both being equally as important. https://everydayastronaut.com/starbase-tour-and-interview-with-elon-musk/

Speakers

Elon Musk

Leadership

Scaling Your Company: Building the Right Team for Growth

In this series, Rory O’Driscoll and Kate Mitchell, founding partners at Scale Venture Partners, will detail the mindset needed to scale your company. Along with some of their associates, they will explain how the scaling phase differs from the startup phase, what kind of metrics you’ll need as you accelerate and what kind of team you’ll need alongside you for the journey ahead.

Speakers

Scale Venture Partners,

Business Strategy and planning

Webinar - Blue Ocean Strategy

Blue ocean strategy is the simultaneous pursuit of differentiation and low cost to open up a new market space and create new demand. It is about creating and capturing uncontested market space, thereby making the competition irrelevant. It is based on the view that market boundaries and industry structure are not a given and can be reconstructed by the actions and beliefs of industry players. https://www.blueoceanstrategy.com/what-is-blue-ocean-strategy/

Speakers

University at Buffalo School of Management

Guissu Baier
Guissu is deeply motivated by a desire to make a lasting impact for companies and the individuals within. After a decade-long legal career as an employment attorney and litigator at the international law firm Littler Mendelson, global payments company Visa and on-demand grocery delivery start-up Instacart, Guissu pursued her passion for people and business strategy to build up the People team at Instacart.
Guissu Baier

The People Collective

Co-Founder

Bill Enright
William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions and eventually taking the company public. Prior to joining Altimmune, Bill spent six years with GenVec, Inc. (acquired by Intrexon) with increasing responsibilities, which included a role as Head of Business Development. He currently serves on the Board of Directors of Gravitas Therapeutics, Inc.
Bill Enright

Vaccitech

CEO

Chris Reichhelm
Founder of Peloton, an executive search and advisory group that builds Boards and executive teams for early and growth-stage Technology and Engineering businesses in the UK and Europe.
Chris Reichhelm

Peloton

CEO & Founder

Kathryn Cavanah
A trusted confidant of the C-suite, Kathryn is known for her ability to dissect problems and offer simple, yet unseen solutions. Kathryn has a passion for people and operations that’s led her to high-impact roles in fast-paced organizations.
Kathryn Cavanah

The People Collective

Co-Founder

Claire Shingler
My mission, through nurturing the BioEscalator community, is to drive positive impact on the Oxford biomedical innovation ecosystem. Following an academic career in chemistry and cancer research, culminating in postdoctoral work in a joint-venture biotech start-up at the University of Edinburgh, Claire’s career has focused on multidisciplinary team management in the biomedical and university sector. Formerly Head of Strategic Intelligence at an Oxford-based pharmaceutical consultancy company, Claire then joined the University of Oxford in 2008, working in research and departmental management in Experimental Medicine and Oncology. Claire took up her role in the BioEscalator as it opened in September 2018. Following an academic career in chemistry and cancer research, culminating in postdoctoral work in a joint-venture biotech start-up at the University of Edinburgh, Claire’s career has focused on multidisciplinary team management in the biomedical and university sector. Formerly Head of Strategic Intelligence at an Oxford-based pharmaceutical consultancy company, Claire then joined the University of Oxford in 2008, working in research and departmental management in Experimental Medicine and Oncology. Claire took up her role in the BioEscalator as it opened in September 2018.
Claire Shingler

BioEscalator

Business manager

Shadi Mahassel
Commercial product executive with strong wireless / mobile, communications and internet consumer applications experience and proven track record of delivering innovative amazing products and customer experiences. Strong technical and product background and strong track record in business development globally.
Shadi Mahassel

Iotics

Vice President, Product

DR GLENN CROCKER MBE
As Head of Life Sciences I bring together the specialist skills of professionals at JLL to address major strategic and operational opportunities and challenges within the life sciences sector. Awarded an MBE for services to the biotech industry in 2014.
DR GLENN CROCKER MBE

JLL

Head of Life Sciences

Alex Hammacker
Alex joined Oxford Science Enterprises as Head of Corporate Finance in October 2019. He was previously a medical student at the University of Oxford and a junior doctor in Oxford before joining investment banking in 2007. Over the course of 13 years, he worked on M&A and capital raising across healthcare, as well as energy and infrastructure. He worked at UBS and then Lazard in Europe and the Australia Pacific region. His experience includes both large pharma and medtech clients as well as early stage biotech and digital health, traditional and renewable energy generation and transmission for private and public market clients. Alex co-ordinates all fundraising and exits across the enterprises, manages the Investment Committee process and reports on the Investment Portfolio. He represents Oxford Science Enterprises on the boards of Vaccitech and Macrophox and is an observer on the board of Evox Therapeutics.
Alex Hammacker

OxSciences

Head of Strategic Operations & Corporate Finance

Paula Skokwoski
Startup executive experienced in launching pioneering technology products, building high performing teams, and scaling companies from zero to later stage revenue growth $100M+. Early employee and executive leader at 5 VC-backed startups: two IPOs, one $1B acquisition, two $500M+ valuations. Highly effective in navigating new market categories, and successfully achieving market leadership. Demonstrated leadership in go-to-market strategy, product definition and development, brand development, marketing and sales enablement.
Paula Skokwoski

Incognia

CMO

Kris Steen
Partner of The Stevenson Group (TSG) since 2015, Kristine has nearly 20 years in Life Sciences executive search. She partners with clients ranging from Pre-Series A ventures to commercial stage life sciences companies across multiple functional areas, from R&D departments to commercial teams, as well as recruiting C-Level executives and Non-Executive Board members. Kristine also leads TSG’s Diversity Initiative with an emphasis on female leadership. Working closely with Women in Bio’s Boardroom Ready Program, Kristine is committed to increasing gender diversity on Boards. She is also a member of WIB’s inaugural National Diversity and Inclusion Resource Group.
Kris Steen

The Stevenson Group

Partner

Matt Morris
he is British motor racing engineer and former chief engineer of the McLaren Formula One team. Morris graduated from Coventry University with a degree in mechanical engineering, joining Cosworth soon after. He remained at Cosworth until 2006, after which he joined Williams, where he stayed for eight years before joining Sauber in 2011. Morris quickly rose up the ranks at Sauber to become their chief designer, a position he held for two seasons before moving back to the UK as McLaren's chief engineer in 2013, a role he held until 26 July 2018 when he resigned.
Matt Morris

Reaction Engines

Engineering Director

Zavain Dar
Zavain is driven by smart software, leveraging data and machine intelligence to scale, augment, and balance human intelligence. He invests in companies that are using machine learning and AI to augment or replace physical-world functions including biology, language, manufacturing and analysis. He looks for entrepreneurs that can use software and data to hone a philosophical position on where the world is, and how to direct it for the better.
Zavain Dar

Lux Capital

Partner

x